nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—SLC22A2—Cytarabine—lymphatic system cancer	0.323	0.444	CbGbCtD
Amantadine—SLC22A1—Cytarabine—lymphatic system cancer	0.281	0.385	CbGbCtD
Amantadine—ABCB1—Mitoxantrone—lymphatic system cancer	0.0593	0.0813	CbGbCtD
Amantadine—ABCB1—Vincristine—lymphatic system cancer	0.0408	0.056	CbGbCtD
Amantadine—ABCB1—Methotrexate—lymphatic system cancer	0.0247	0.0339	CbGbCtD
Amantadine—Alopecia—Fludarabine—lymphatic system cancer	0.00141	0.00522	CcSEcCtD
Amantadine—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00141	0.0052	CcSEcCtD
Amantadine—Malnutrition—Fludarabine—lymphatic system cancer	0.00139	0.00514	CcSEcCtD
Amantadine—Ataxia—Carmustine—lymphatic system cancer	0.00139	0.00513	CcSEcCtD
Amantadine—Hypertension—Teniposide—lymphatic system cancer	0.00137	0.00505	CcSEcCtD
Amantadine—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00136	0.00504	CcSEcCtD
Amantadine—Paralysis—Methotrexate—lymphatic system cancer	0.00136	0.00501	CcSEcCtD
Amantadine—Cardiac arrest—Vincristine—lymphatic system cancer	0.00134	0.00496	CcSEcCtD
Amantadine—Urinary retention—Vincristine—lymphatic system cancer	0.00134	0.00496	CcSEcCtD
Amantadine—Ataxia—Vincristine—lymphatic system cancer	0.00133	0.0049	CcSEcCtD
Amantadine—Confusional state—Teniposide—lymphatic system cancer	0.0013	0.00481	CcSEcCtD
Amantadine—Oedema—Teniposide—lymphatic system cancer	0.00129	0.00477	CcSEcCtD
Amantadine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00129	0.00477	CcSEcCtD
Amantadine—Agitation—Fludarabine—lymphatic system cancer	0.00128	0.00472	CcSEcCtD
Amantadine—Dysphagia—Carmustine—lymphatic system cancer	0.00128	0.00472	CcSEcCtD
Amantadine—Stupor—Methotrexate—lymphatic system cancer	0.00126	0.00467	CcSEcCtD
Amantadine—Tachycardia—Teniposide—lymphatic system cancer	0.00126	0.00466	CcSEcCtD
Amantadine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00125	0.00461	CcSEcCtD
Amantadine—Leukopenia—Fludarabine—lymphatic system cancer	0.00124	0.0046	CcSEcCtD
Amantadine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00124	0.00458	CcSEcCtD
Amantadine—Anorexia—Teniposide—lymphatic system cancer	0.00123	0.00455	CcSEcCtD
Amantadine—Hypotension—Teniposide—lymphatic system cancer	0.00121	0.00446	CcSEcCtD
Amantadine—Convulsion—Fludarabine—lymphatic system cancer	0.0012	0.00445	CcSEcCtD
Amantadine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.0012	0.00443	CcSEcCtD
Amantadine—Neutropenia—Carmustine—lymphatic system cancer	0.00119	0.00441	CcSEcCtD
Amantadine—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00116	0.00427	CcSEcCtD
Amantadine—Dyspnoea—Teniposide—lymphatic system cancer	0.00115	0.00425	CcSEcCtD
Amantadine—Confusional state—Fludarabine—lymphatic system cancer	0.00114	0.00423	CcSEcCtD
Amantadine—Neutropenia—Vincristine—lymphatic system cancer	0.00114	0.00421	CcSEcCtD
Amantadine—Oedema—Fludarabine—lymphatic system cancer	0.00113	0.00419	CcSEcCtD
Amantadine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00113	0.00419	CcSEcCtD
Amantadine—Decreased appetite—Teniposide—lymphatic system cancer	0.00112	0.00415	CcSEcCtD
Amantadine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00111	0.00411	CcSEcCtD
Amantadine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00111	0.00411	CcSEcCtD
Amantadine—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00111	0.00411	CcSEcCtD
Amantadine—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00111	0.0041	CcSEcCtD
Amantadine—Rash—Mechlorethamine—lymphatic system cancer	0.0011	0.00408	CcSEcCtD
Amantadine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0011	0.00408	CcSEcCtD
Amantadine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.0011	0.00405	CcSEcCtD
Amantadine—Anorexia—Fludarabine—lymphatic system cancer	0.00108	0.004	CcSEcCtD
Amantadine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00106	0.00393	CcSEcCtD
Amantadine—Nausea—Mechlorethamine—lymphatic system cancer	0.00104	0.00384	CcSEcCtD
Amantadine—Alopecia—Bleomycin—lymphatic system cancer	0.00103	0.00382	CcSEcCtD
Amantadine—Body temperature increased—Teniposide—lymphatic system cancer	0.00102	0.00377	CcSEcCtD
Amantadine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00102	0.00377	CcSEcCtD
Amantadine—Hallucination—Carmustine—lymphatic system cancer	0.00102	0.00376	CcSEcCtD
Amantadine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00101	0.00374	CcSEcCtD
Amantadine—Oedema peripheral—Carmustine—lymphatic system cancer	0.00101	0.00372	CcSEcCtD
Amantadine—Dyspepsia—Fludarabine—lymphatic system cancer	0.000999	0.00369	CcSEcCtD
Amantadine—Dysarthria—Methotrexate—lymphatic system cancer	0.000997	0.00368	CcSEcCtD
Amantadine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000988	0.00365	CcSEcCtD
Amantadine—Decreased appetite—Fludarabine—lymphatic system cancer	0.000987	0.00365	CcSEcCtD
Amantadine—Visual impairment—Carmustine—lymphatic system cancer	0.000985	0.00364	CcSEcCtD
Amantadine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00098	0.00362	CcSEcCtD
Amantadine—Fatigue—Fludarabine—lymphatic system cancer	0.000978	0.00362	CcSEcCtD
Amantadine—Hallucination—Vincristine—lymphatic system cancer	0.000971	0.00359	CcSEcCtD
Amantadine—Constipation—Fludarabine—lymphatic system cancer	0.000971	0.00359	CcSEcCtD
Amantadine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000964	0.00356	CcSEcCtD
Amantadine—Urethral disorder—Vincristine—lymphatic system cancer	0.000957	0.00353	CcSEcCtD
Amantadine—Eye disorder—Carmustine—lymphatic system cancer	0.000955	0.00353	CcSEcCtD
Amantadine—Hypersensitivity—Teniposide—lymphatic system cancer	0.000951	0.00352	CcSEcCtD
Amantadine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000935	0.00346	CcSEcCtD
Amantadine—Asthenia—Teniposide—lymphatic system cancer	0.000926	0.00342	CcSEcCtD
Amantadine—Pruritus—Teniposide—lymphatic system cancer	0.000914	0.00338	CcSEcCtD
Amantadine—Arrhythmia—Carmustine—lymphatic system cancer	0.000913	0.00337	CcSEcCtD
Amantadine—Leukopenia—Bleomycin—lymphatic system cancer	0.000913	0.00337	CcSEcCtD
Amantadine—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000911	0.00336	CcSEcCtD
Amantadine—Cardiac disorder—Vincristine—lymphatic system cancer	0.000906	0.00335	CcSEcCtD
Amantadine—Alopecia—Carmustine—lymphatic system cancer	0.000903	0.00334	CcSEcCtD
Amantadine—Body temperature increased—Fludarabine—lymphatic system cancer	0.000897	0.00331	CcSEcCtD
Amantadine—Mental disorder—Carmustine—lymphatic system cancer	0.000896	0.00331	CcSEcCtD
Amantadine—Malnutrition—Carmustine—lymphatic system cancer	0.00089	0.00329	CcSEcCtD
Amantadine—Angiopathy—Vincristine—lymphatic system cancer	0.000885	0.00327	CcSEcCtD
Amantadine—Diarrhoea—Teniposide—lymphatic system cancer	0.000884	0.00326	CcSEcCtD
Amantadine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00088	0.00325	CcSEcCtD
Amantadine—Alopecia—Vincristine—lymphatic system cancer	0.000862	0.00319	CcSEcCtD
Amantadine—Coma—Methotrexate—lymphatic system cancer	0.000862	0.00318	CcSEcCtD
Amantadine—Mental disorder—Vincristine—lymphatic system cancer	0.000855	0.00316	CcSEcCtD
Amantadine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000849	0.00314	CcSEcCtD
Amantadine—Alopecia—Mitoxantrone—lymphatic system cancer	0.00084	0.0031	CcSEcCtD
Amantadine—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000839	0.0031	CcSEcCtD
Amantadine—Confusional state—Bleomycin—lymphatic system cancer	0.000839	0.0031	CcSEcCtD
Amantadine—Vision blurred—Carmustine—lymphatic system cancer	0.000839	0.0031	CcSEcCtD
Amantadine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000836	0.00309	CcSEcCtD
Amantadine—Tremor—Carmustine—lymphatic system cancer	0.000834	0.00308	CcSEcCtD
Amantadine—Oedema—Bleomycin—lymphatic system cancer	0.000832	0.00307	CcSEcCtD
Amantadine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000832	0.00307	CcSEcCtD
Amantadine—Vomiting—Teniposide—lymphatic system cancer	0.000821	0.00303	CcSEcCtD
Amantadine—Agitation—Carmustine—lymphatic system cancer	0.000818	0.00302	CcSEcCtD
Amantadine—Asthenia—Fludarabine—lymphatic system cancer	0.000814	0.00301	CcSEcCtD
Amantadine—Rash—Teniposide—lymphatic system cancer	0.000814	0.00301	CcSEcCtD
Amantadine—Dermatitis—Teniposide—lymphatic system cancer	0.000813	0.00301	CcSEcCtD
Amantadine—Headache—Teniposide—lymphatic system cancer	0.000809	0.00299	CcSEcCtD
Amantadine—Pruritus—Fludarabine—lymphatic system cancer	0.000803	0.00297	CcSEcCtD
Amantadine—Leukopenia—Carmustine—lymphatic system cancer	0.000797	0.00294	CcSEcCtD
Amantadine—Anorexia—Bleomycin—lymphatic system cancer	0.000793	0.00293	CcSEcCtD
Amantadine—Agitation—Vincristine—lymphatic system cancer	0.000781	0.00288	CcSEcCtD
Amantadine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00078	0.00288	CcSEcCtD
Amantadine—Photosensitivity—Methotrexate—lymphatic system cancer	0.00078	0.00288	CcSEcCtD
Amantadine—Hypotension—Bleomycin—lymphatic system cancer	0.000778	0.00287	CcSEcCtD
Amantadine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000777	0.00287	CcSEcCtD
Amantadine—Convulsion—Carmustine—lymphatic system cancer	0.000771	0.00285	CcSEcCtD
Amantadine—Hypertension—Carmustine—lymphatic system cancer	0.000768	0.00284	CcSEcCtD
Amantadine—Nausea—Teniposide—lymphatic system cancer	0.000767	0.00283	CcSEcCtD
Amantadine—Leukopenia—Vincristine—lymphatic system cancer	0.00076	0.00281	CcSEcCtD
Amantadine—Anxiety—Carmustine—lymphatic system cancer	0.000755	0.00279	CcSEcCtD
Amantadine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000747	0.00276	CcSEcCtD
Amantadine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000742	0.00274	CcSEcCtD
Amantadine—Renal failure acute—Methotrexate—lymphatic system cancer	0.000741	0.00274	CcSEcCtD
Amantadine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000741	0.00274	CcSEcCtD
Amantadine—Convulsion—Vincristine—lymphatic system cancer	0.000736	0.00272	CcSEcCtD
Amantadine—Hypertension—Vincristine—lymphatic system cancer	0.000733	0.00271	CcSEcCtD
Amantadine—Confusional state—Carmustine—lymphatic system cancer	0.000732	0.00271	CcSEcCtD
Amantadine—Oedema—Carmustine—lymphatic system cancer	0.000726	0.00268	CcSEcCtD
Amantadine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000723	0.00267	CcSEcCtD
Amantadine—Visual disturbance—Methotrexate—lymphatic system cancer	0.000722	0.00267	CcSEcCtD
Amantadine—Vomiting—Fludarabine—lymphatic system cancer	0.000722	0.00267	CcSEcCtD
Amantadine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000717	0.00265	CcSEcCtD
Amantadine—Rash—Fludarabine—lymphatic system cancer	0.000716	0.00264	CcSEcCtD
Amantadine—Dermatitis—Fludarabine—lymphatic system cancer	0.000715	0.00264	CcSEcCtD
Amantadine—Hypertension—Mitoxantrone—lymphatic system cancer	0.000714	0.00264	CcSEcCtD
Amantadine—Headache—Fludarabine—lymphatic system cancer	0.000711	0.00263	CcSEcCtD
Amantadine—Tachycardia—Carmustine—lymphatic system cancer	0.000709	0.00262	CcSEcCtD
Amantadine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000702	0.00259	CcSEcCtD
Amantadine—Lethargy—Methotrexate—lymphatic system cancer	0.000699	0.00258	CcSEcCtD
Amantadine—Oedema—Vincristine—lymphatic system cancer	0.000693	0.00256	CcSEcCtD
Amantadine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000693	0.00256	CcSEcCtD
Amantadine—Anorexia—Carmustine—lymphatic system cancer	0.000692	0.00256	CcSEcCtD
Amantadine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000686	0.00253	CcSEcCtD
Amantadine—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000685	0.00253	CcSEcCtD
Amantadine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000681	0.00252	CcSEcCtD
Amantadine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00068	0.00251	CcSEcCtD
Amantadine—Hypotension—Carmustine—lymphatic system cancer	0.000679	0.00251	CcSEcCtD
Amantadine—Oedema—Mitoxantrone—lymphatic system cancer	0.000675	0.00249	CcSEcCtD
Amantadine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000675	0.00249	CcSEcCtD
Amantadine—Nausea—Fludarabine—lymphatic system cancer	0.000674	0.00249	CcSEcCtD
Amantadine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00067	0.00248	CcSEcCtD
Amantadine—Anorexia—Vincristine—lymphatic system cancer	0.000661	0.00244	CcSEcCtD
Amantadine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000659	0.00243	CcSEcCtD
Amantadine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000658	0.00243	CcSEcCtD
Amantadine—Insomnia—Carmustine—lymphatic system cancer	0.000657	0.00243	CcSEcCtD
Amantadine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000656	0.00242	CcSEcCtD
Amantadine—Irritability—Methotrexate—lymphatic system cancer	0.000653	0.00241	CcSEcCtD
Amantadine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000653	0.00241	CcSEcCtD
Amantadine—Paraesthesia—Carmustine—lymphatic system cancer	0.000652	0.00241	CcSEcCtD
Amantadine—Hypotension—Vincristine—lymphatic system cancer	0.000648	0.00239	CcSEcCtD
Amantadine—Dyspnoea—Carmustine—lymphatic system cancer	0.000648	0.00239	CcSEcCtD
Amantadine—Somnolence—Carmustine—lymphatic system cancer	0.000646	0.00239	CcSEcCtD
Amantadine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000644	0.00238	CcSEcCtD
Amantadine—Ataxia—Methotrexate—lymphatic system cancer	0.000644	0.00238	CcSEcCtD
Amantadine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000632	0.00233	CcSEcCtD
Amantadine—Decreased appetite—Carmustine—lymphatic system cancer	0.000631	0.00233	CcSEcCtD
Amantadine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000631	0.00233	CcSEcCtD
Amantadine—Insomnia—Vincristine—lymphatic system cancer	0.000627	0.00232	CcSEcCtD
Amantadine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000627	0.00232	CcSEcCtD
Amantadine—Paraesthesia—Vincristine—lymphatic system cancer	0.000623	0.0023	CcSEcCtD
Amantadine—Constipation—Carmustine—lymphatic system cancer	0.000621	0.00229	CcSEcCtD
Amantadine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000613	0.00227	CcSEcCtD
Amantadine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000606	0.00224	CcSEcCtD
Amantadine—Decreased appetite—Vincristine—lymphatic system cancer	0.000603	0.00223	CcSEcCtD
Amantadine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000602	0.00222	CcSEcCtD
Amantadine—Somnolence—Mitoxantrone—lymphatic system cancer	0.0006	0.00222	CcSEcCtD
Amantadine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000599	0.00221	CcSEcCtD
Amantadine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000599	0.00221	CcSEcCtD
Amantadine—Fatigue—Vincristine—lymphatic system cancer	0.000598	0.00221	CcSEcCtD
Amantadine—Asthenia—Bleomycin—lymphatic system cancer	0.000597	0.00221	CcSEcCtD
Amantadine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000594	0.0022	CcSEcCtD
Amantadine—Constipation—Vincristine—lymphatic system cancer	0.000593	0.00219	CcSEcCtD
Amantadine—Pruritus—Bleomycin—lymphatic system cancer	0.000589	0.00218	CcSEcCtD
Amantadine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000587	0.00217	CcSEcCtD
Amantadine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000582	0.00215	CcSEcCtD
Amantadine—Constipation—Mitoxantrone—lymphatic system cancer	0.000577	0.00213	CcSEcCtD
Amantadine—Body temperature increased—Carmustine—lymphatic system cancer	0.000574	0.00212	CcSEcCtD
Amantadine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000556	0.00206	CcSEcCtD
Amantadine—Neutropenia—Methotrexate—lymphatic system cancer	0.000553	0.00204	CcSEcCtD
Amantadine—Body temperature increased—Vincristine—lymphatic system cancer	0.000548	0.00203	CcSEcCtD
Amantadine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00054	0.002	CcSEcCtD
Amantadine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000535	0.00198	CcSEcCtD
Amantadine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000534	0.00197	CcSEcCtD
Amantadine—Vomiting—Bleomycin—lymphatic system cancer	0.000529	0.00195	CcSEcCtD
Amantadine—Rash—Bleomycin—lymphatic system cancer	0.000525	0.00194	CcSEcCtD
Amantadine—Dermatitis—Bleomycin—lymphatic system cancer	0.000524	0.00194	CcSEcCtD
Amantadine—Asthenia—Carmustine—lymphatic system cancer	0.000521	0.00193	CcSEcCtD
Amantadine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000511	0.00189	CcSEcCtD
Amantadine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000498	0.00184	CcSEcCtD
Amantadine—Asthenia—Vincristine—lymphatic system cancer	0.000497	0.00184	CcSEcCtD
Amantadine—Diarrhoea—Carmustine—lymphatic system cancer	0.000497	0.00184	CcSEcCtD
Amantadine—Nausea—Bleomycin—lymphatic system cancer	0.000494	0.00183	CcSEcCtD
Amantadine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000492	0.00182	CcSEcCtD
Amantadine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000484	0.00179	CcSEcCtD
Amantadine—Dizziness—Carmustine—lymphatic system cancer	0.00048	0.00177	CcSEcCtD
Amantadine—Diarrhoea—Vincristine—lymphatic system cancer	0.000474	0.00175	CcSEcCtD
Amantadine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000468	0.00173	CcSEcCtD
Amantadine—Urethral disorder—Methotrexate—lymphatic system cancer	0.000464	0.00172	CcSEcCtD
Amantadine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000462	0.00171	CcSEcCtD
Amantadine—Vomiting—Carmustine—lymphatic system cancer	0.000462	0.00171	CcSEcCtD
Amantadine—Dizziness—Vincristine—lymphatic system cancer	0.000459	0.00169	CcSEcCtD
Amantadine—Rash—Carmustine—lymphatic system cancer	0.000458	0.00169	CcSEcCtD
Amantadine—Dermatitis—Carmustine—lymphatic system cancer	0.000458	0.00169	CcSEcCtD
Amantadine—Visual impairment—Methotrexate—lymphatic system cancer	0.000456	0.00169	CcSEcCtD
Amantadine—Headache—Carmustine—lymphatic system cancer	0.000455	0.00168	CcSEcCtD
Amantadine—Eye disorder—Methotrexate—lymphatic system cancer	0.000443	0.00164	CcSEcCtD
Amantadine—Vomiting—Vincristine—lymphatic system cancer	0.000441	0.00163	CcSEcCtD
Amantadine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000439	0.00162	CcSEcCtD
Amantadine—Rash—Vincristine—lymphatic system cancer	0.000437	0.00162	CcSEcCtD
Amantadine—Dermatitis—Vincristine—lymphatic system cancer	0.000437	0.00161	CcSEcCtD
Amantadine—Headache—Vincristine—lymphatic system cancer	0.000434	0.0016	CcSEcCtD
Amantadine—Nausea—Carmustine—lymphatic system cancer	0.000431	0.00159	CcSEcCtD
Amantadine—Angiopathy—Methotrexate—lymphatic system cancer	0.00043	0.00159	CcSEcCtD
Amantadine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000429	0.00159	CcSEcCtD
Amantadine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000427	0.00158	CcSEcCtD
Amantadine—Rash—Mitoxantrone—lymphatic system cancer	0.000426	0.00157	CcSEcCtD
Amantadine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000425	0.00157	CcSEcCtD
Amantadine—Headache—Mitoxantrone—lymphatic system cancer	0.000423	0.00156	CcSEcCtD
Amantadine—Alopecia—Methotrexate—lymphatic system cancer	0.000418	0.00155	CcSEcCtD
Amantadine—Mental disorder—Methotrexate—lymphatic system cancer	0.000415	0.00153	CcSEcCtD
Amantadine—Malnutrition—Methotrexate—lymphatic system cancer	0.000412	0.00152	CcSEcCtD
Amantadine—Nausea—Vincristine—lymphatic system cancer	0.000412	0.00152	CcSEcCtD
Amantadine—Nausea—Mitoxantrone—lymphatic system cancer	0.000401	0.00148	CcSEcCtD
Amantadine—Vision blurred—Methotrexate—lymphatic system cancer	0.000388	0.00144	CcSEcCtD
Amantadine—Leukopenia—Methotrexate—lymphatic system cancer	0.000369	0.00136	CcSEcCtD
Amantadine—Convulsion—Methotrexate—lymphatic system cancer	0.000357	0.00132	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000349	0.00129	CcSEcCtD
Amantadine—Confusional state—Methotrexate—lymphatic system cancer	0.000339	0.00125	CcSEcCtD
Amantadine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000336	0.00124	CcSEcCtD
Amantadine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00033	0.00122	CcSEcCtD
Amantadine—Skin disorder—Methotrexate—lymphatic system cancer	0.000327	0.00121	CcSEcCtD
Amantadine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000325	0.0012	CcSEcCtD
Amantadine—Anorexia—Methotrexate—lymphatic system cancer	0.000321	0.00118	CcSEcCtD
Amantadine—Hypotension—Methotrexate—lymphatic system cancer	0.000314	0.00116	CcSEcCtD
Amantadine—Insomnia—Methotrexate—lymphatic system cancer	0.000304	0.00112	CcSEcCtD
Amantadine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000302	0.00112	CcSEcCtD
Amantadine—Dyspnoea—Methotrexate—lymphatic system cancer	0.0003	0.00111	CcSEcCtD
Amantadine—Somnolence—Methotrexate—lymphatic system cancer	0.000299	0.00111	CcSEcCtD
Amantadine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000296	0.00109	CcSEcCtD
Amantadine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000292	0.00108	CcSEcCtD
Amantadine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00029	0.00107	CcSEcCtD
Amantadine—Fatigue—Methotrexate—lymphatic system cancer	0.00029	0.00107	CcSEcCtD
Amantadine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000277	0.00102	CcSEcCtD
Amantadine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000266	0.000983	CcSEcCtD
Amantadine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000248	0.000916	CcSEcCtD
Amantadine—Asthenia—Methotrexate—lymphatic system cancer	0.000241	0.000892	CcSEcCtD
Amantadine—Pruritus—Methotrexate—lymphatic system cancer	0.000238	0.000879	CcSEcCtD
Amantadine—Diarrhoea—Methotrexate—lymphatic system cancer	0.00023	0.000851	CcSEcCtD
Amantadine—Dizziness—Methotrexate—lymphatic system cancer	0.000222	0.000822	CcSEcCtD
Amantadine—Vomiting—Methotrexate—lymphatic system cancer	0.000214	0.00079	CcSEcCtD
Amantadine—Rash—Methotrexate—lymphatic system cancer	0.000212	0.000784	CcSEcCtD
Amantadine—Dermatitis—Methotrexate—lymphatic system cancer	0.000212	0.000783	CcSEcCtD
Amantadine—Headache—Methotrexate—lymphatic system cancer	0.000211	0.000779	CcSEcCtD
Amantadine—Nausea—Methotrexate—lymphatic system cancer	0.0002	0.000738	CcSEcCtD
